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ABSTRACT 
Purpose: Members of the mitochondrial carrier family (SLC25) transport metabolites, 
nucleotides, co-factors and inorganic ions across the mitochondrial inner membrane.  
Methods: We identified a pathogenic variant in a novel mitochondrial carrier gene in a 
patient by whole exome sequencing. The pathogenicity of the mutation was studied by 
transport assays, computer modelling followed by targeted metabolic testing and in vitro 
studies in human fibroblasts and neurons. 
Results: The patient carries a homozygous pathogenic variant c.695A>G; p.(Lys232Arg) in 
the SLC25A21 gene, encoding the mitochondrial oxodicarboxylate carrier, and developed 
spinal muscular atrophy and mitochondrial myopathy. Transport assays show that the 
mutation renders SLC25A21 dysfunctional and 2-oxoadipate cannot be imported into the 
mitochondrial matrix. Computer models of central metabolism predicted that impaired 
transport of oxodicarboxylate disrupts the pathways of lysine and tryptophan degradation, and 
causes accumulation of 2-oxoadipate, pipecolic acid and quinolinic acid, which was 
confirmed in the patient’s urine by targeted metabolomics. Exposure to 2-oxoadipate and 
quinolinic acid decreased the level of mitochondrial complexes in neuronal cells (SH-SY5Y) 
and induced apoptosis.  
Conclusion: Mitochondrial oxodicarboxylate carrier deficiency leads to mitochondrial 
dysfunction and the accumulation of oxoadipate and quinolinic acid, which in turn cause 
toxicity in spinal motor neurons leading to spinal muscular atrophy-like disease. 
 
Key words: metabolite transport, spinal motor atrophy, mitochondrial respiratory chain 
deficiency, neural toxicity, metabolomics. 
 
 4 
Abbreviations: SLC25A21 mitochondrial oxodicarboxylate carrier; FVC forced vital 
capacity; SMA spinal muscular atrophy; CK creatine kinase; CSF cerebrospinal fluid; COX 
cytochrome c oxidase; mtDNA mitochondrial DNA. 
  
 5 
INTRODUCTION 
Several inherited diseases with very variable clinical presentations are associated with 
dysfunctional mitochondrial carriers (SLC25), which transport nucleotides, keto acids, amino 
acids, fatty acids, co-factors and inorganic ions across the mitochondrial inner membrane1-5. 
They cause various metabolic syndromes often affecting skeletal muscle (e.g. 
rhabdomyolysis, lipid storage myopathy, and neuromuscular transmission), heart 
(cardiomyopathy) or the nervous system (e.g. neuropathy, neonatal epileptic encephalopathy, 
and optic atrophy)1-3. The heterogeneous clinical presentations of mitochondrial carrier 
deficiencies may be explained by the wide range of different substrates transported by 
mitochondrial carriers and their different roles in intermediary metabolism1. 
SLC25A21 transports 2-oxoadipate and 2-oxoglutarate across the inner membrane of 
mitochondria by a counter-exchange mechanism6. We report a patient who presented with 
spinal muscular atrophy (SMA) and mitochondrial myopathy and we show that this is due to a 
dysfunctional mitochondrial oxodicarboxylate carrier (SLC25A21) caused by a homozygous 
c.695A>G mutation. Although the p.(Lys232Arg) amino acid change is conservative, we 
show that the novel pathogenic variant cannot transport substrates, demonstrating a direct 
functional link. We were able to identify the molecular aetiology of the disorder by 
combining computer-modelling of the effect of defective transport on central metabolism, 
targeted metabolomics and in vitro studies in human fibroblasts and neuronal cells. 
 
MATERIALS AND METHODS 
Whole exome sequencing 
Exome sequencing was performed on blood DNA using the Illumina Truseq 62Mb exome 
capture kit and a HiSeq 2000. Duplicate sequence reads were removed with Fastuniq (v1.1) 
before alignment against the human UCSC hg38 reference genome using BWA (v0.7.12). 
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Coding bases had a mean read depth of 69.6-fold and 90.6% of these bases were covered to a 
minimum read depth of 10-fold. Sequence variants were called using Samtools/Bcftools 
(v1.3), followed by annotation with Annovar (Jan 2016 download) and filtering for rare, 
evolutionarily conserved, predicted damaging and with known mitochondrial function using 
custom Perl scripts and in silico effects were evaluated following the American College of 
Medical Genetics and Genomics guidelines7. The exome pipeline and variant filtering scripts 
are available from github (https://github.com/Helgriff/Exome-Pipe). Confirmation of the 
selected mutations was performed by Sanger sequencing. 
 
SDS-PAGE and BN-PAGE analysis 
For western blotting, whole cell lysates or mitochondrial extracts isolated from skeletal 
muscle tissue (50 µg) were separated by SDS-PAGE (12%). For BN-PAGE mitochondria 
were extracted from control and patient muscle as previously described8. The antibodies used 
are listed in Supplementary file 1).  
 
Transport studies of SLC25A21 expressed in Lactococcus lactis 
A codon-optimised SLC25A21 gene was synthesized by GenScript (Piscataway, USA), and 
cloned into the expression vector pNZ8048 under the control of a nisin A-inducible 
promoter9. An N-terminal truncation of human oxodicarboxylate carrier (∆2-4) was used to 
increase transport activity (Supplementary file 1. Supplementary methods and 
supplementary figure 2). 
Transport assays were carried out using a Hamilton MicroLab Star robot (Hamilton 
Robotics Ltd). Transport of [14C]-2-oxoglutarate (American Radiolabeled Chemicals) was 
initiated by the addition of 100 μl PIPES buffer with 2.5 μM labeled 2-oxoglutarate (2.04 
GBq/ mmol) to 5 μg fused membranes in a MultiScreenHTS-HA 96-well filter plate (pore 
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size 0.45 μm; Millipore). The transport was stopped at 0, 60, 120, 300 sec, 10, 15, 20 and 30 
min by the addition of 200 μl ice-cold PIPES buffer and filtering using a vacuum manifold, 
followed by two additional wash steps with 200 μl ice-cold PIPES buffer. Levels of 
radioactivity in the vesicles were measured by the addition of 200 μl MicroScint-20 (Perkin 
Elmer) and by quantifying the amount of radioactivity (TopCount scintillation counter, Perkin 
Elmer). Initial rates were determined using linear regression. 
 
Computational modelling of SLC25A21 deficiency 
Simulations of metabolism during impaired oxodicarboxylate transport were performed by 
using the MitoCore metabolic model10. Several alterations were made to the default model 
including the incorporation of five additional reactions involved in the production of 
tryptophan intermediates and the addition of seven ‘sinks’ to allow the efflux of tryptophan 
and lysine degradation intermediates: quinolinic acid, 2-oxoadipate, kynurenic acid, 
xanthurenic acid, L-2-aminoadipate, L-pipecolate and picolinic acid (the adapted model is 
available upon request). The default uptake parameters of two ‘fuel’ metabolites were altered 
to prevent their excessive uptake relative to oxygen availability; fatty acids (hexadecanoate) 
was set at a maximum uptake of 0.4 μmol/min/gDW and the uptake of acetate was prevented. 
A minimum uptake flux of cytosolic L-lysine and L-tryptophan was set at a rate recorded 
experimentally for rat heart tissue11. As two separate pathways exist to degrade lysine, the 
reaction for aminoadipate-semialdehyde synthase (ID:R_SACCD3m), part of the 
saccharopine pathway, was restricted to half of the uptake of lysine. To simulate SLC25A21 
dysfunction, the representative transport steps in the model were disabled (IDs: 
R_2OXOADPTmB_MitoCore, R_2OXOADPTmC_MitoCore, R_2AMADPTmB_MitoCore, 
and R_2AMADPTmC_MitoCore). Further simulations were performed where the efflux of 
quinolinic acid and pipecolate were prevented. The system was simulated with Flux Balance 
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Analysis12 using the objective function of maximum ATP production. Simulations were 
performed in MatLab (MathWorks, Inc., Natick, MA), using the COBRA toolbox12 and the 
GLPK solver (http://www.gnu.org/software/glpk/).  
 
Metabolite analysis by mass spectrometry 
Metabolite measurements were performed by ultrahigh-performance liquid chromatography - 
tandem mass spectrometry (UPLC-MS/MS) on an Agilent 1290 UHPLC system coupled to a 
Sciex 4000 QTRAP mass spectrometer. For sample preparation, 45 μl of each sample was 
mixed with 105 μl of acetonitrile.  After vortex mixing for 15 s and sonication in an ice-water 
bath for 1 min, the samples were centrifuged (14,000 x g, 10 min, 4 °C). The supernatants 
were used for quantitation of the metabolites using two different UPLC-MRM/MS methods, 
as described13 (Supplementary file 1, Supplementary methods).  
 
Cell culture studies  
Age-matched control and patient fibroblasts from the Newcastle Biobank were grown in high 
glucose Dulbecco’s modified Eagle’s medium (DMEM, Sigma, Poole, UK) supplemented 
with 10% FBS and 1% penicillin/streptomycin. SH-SY5Y cells were grown in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM 
glutamine, and 1% penicillin/streptomycin. Blue native polyacrylamide gel electrophoresis 
(BN-PAGE) of the mitochondrial respiratory chain complexes was performed as described 
previously14. For drug toxicity studies growth medium was supplemented with 5 and 50 µM 
2-oxoadipic acid (Sigma 75447) and quinolinic acid (Sigma) respectively for 4 days before 
analysis. Experiments were done in triplicates. 
 
Study of apoptosis in cell cultures with Annexin V-FITC/Propidium Iodide staining 
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Cell apoptosis was assessed using an Annexin V-FITC/Propidium Iodide (PI) Apoptosis 
Detection Kit (Abcam)(Supplementary file 1, Supplementary methods) 
 
Quantification of mitochondrial DNA copy number 
 Quantification of mtDNA copy number was performed using CFX96 Touch™ Real-Time 
PCR Detection System (Bio-Rad) in triplicate by duplex TaqMan qPCR amplification of the 
mitochondrial gene MTND1 and the nuclear encoded gene B2M as described previously15.  
 
RESULTS 
Patient 
Written consent for the study and for photos was provided by the patient and family members, 
and approved by the local ethics committee (REC 13/YH/0310). 
The patient is a 19-year-old daughter (Fig. 1a) of consanguineous Pakistani parents. 
She was born at full term with a weight of 3180 g, had normal early development and was 
walking by 15 months. Between age 3 and 5 years her walking deteriorated slowly with 
frequent falls. Aged 5 years her small hand muscles became wasted and clawed, and she 
developed bilateral foot drop, failure to thrive and scoliosis. On examination, mild facial 
weakness and tongue fasciculations were noted. Proximal muscle strength was normal, but 
distal muscle weakness and atrophy in both hands and feet were present. Deep tendon reflexes 
were brisk in the lower limbs with clonus at the ankles. She was walking with foot drop. 
Forced vital capacity (FVC) was 0.74L (56% of predicted normal value) in a sitting position. 
Between 8-15 years of age, she deteriorated further with proximal weakness, 
intermittent relapses triggered by fever, and became wheelchair-bound at age 15. At age 18 
she had developed severe weakness (2/5 MRC grade) resulting in inability to stand with 
absent deep tendon reflexes. Pulmonary function testing showed a FVC of 65%.  
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Routine laboratory tests were unremarkable, including renal and liver function, except 
for a constant microcytic anaemia (mean corpuscular volume: 53.9-55.9 fl; haemoglobin 8.6-
10.5 g/dl; hematocrit 0.306-0.340%). She had normal levels of creatine kinase (CK), lactate, 
folate, vitamin E and B12, very long chain fatty acids and phytanic acid. White cell enzymes 
were normal, including hexoseaminidase and arylsulfatase. Analyses of amino acids in serum 
and urine showed a slight, but reproducible increase in lysine, histidine, threonine, serine, 
glycine, tyrosine, cysteine dimer, alanine and asparagine. Analyses of the organic acids in 
urine showed some lactic aciduria and slightly increased excretion of 3-hydroxyisovaleric and 
glutaric acids. Plasma free and total carnitine levels were within acceptable ranges. 
Cerebrospinal fluid (CSF) was acellular with normal protein and amino acids, but lactate was 
marginally elevated (2.09 mmol/l versus normal of less than 2 mmol/l). Cranial and spinal 
MRIs were unremarkable.  
Neurophysiological examination showed severe neurogenic change consistent with an 
anterior horn cell process. A nerve biopsy suggested an axonopathy, with mild and patchy 
loss of myelinated fibres. Electron microscopy showed many fibres accumulating 
membranous and granule debris, and glycogen deposits in the cytoplasm of the Schwann cells 
(data not shown).  
 
Genetic analysis of the patient’s exome 
Exome sequencing of the patient’s genomic DNA identified three homozygous rare missense 
variants in SLC25A21, DTNA and HCCS (minor allele frequency < 0.01) that were predicted 
as “probably damaging” by SIFT, Polyphen-2, LRT, Mutation Taster, FATHMM, 
PROVEAN and CADD. Segregation analysis in the patient, both parents and an unaffected 
sister showed segregation only with the c.695A>G; p.(Lys232Arg) mutation in SLC25A21, 
encoding the mitochondrial oxodicarboxylate carrier protein (SLC25A21)(Fig. 1b), which 
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transports 2-oxoadipate into the mitochondrion in exchange for oxoglutarate. This mutation 
was absent from the ExAC control database (http://exac.broadinstitute.org/), but reported in 
gnomAD as a heterozygous variant in a single individual from South Asia 
(http://gnomad.broadinstitute.org/variant/14-37154039-T-C). This region encompasses the 
patient’s Pakistani heritage and suggests she may not be a unique case amongst this 
population. To identify further undiagnosed cases of mitochondrial oxodicarboxylate carrier 
deficiency, we searched for patients with a similar phenotype and carrying mutations in the 
SLC25A21 gene in various international match-making databases, including RD-CONNECT 
(http://rd-connect.eu/), GeneMatcher (http://genematcher.org) and Matchmaker Exchange 
(www.matchmakerexchange.org), but we did not identify any other cases suggesting the rarity 
of this disease. The exome sequencing data were deposited in the RD-CONNECT database. 
We studied the effect of this mutation on the expression and function of the SLC25A21 
protein.  
 
Skeletal muscle biopsy 
A muscle biopsy at 8 years of age suggested neurogenic atrophy with grouping of smaller 
predominantly type I fibres and increased adipose tissue. (Fig. 1c) Oxidative enzyme 
histochemistry revealed numerous cytochrome c oxidase (COX) deficient fibres (Fig. 1d) 
with direct biochemical assay of respiratory chain function revealing decreased activities of 
complex I (0.026 nmols/ UCS, normal range 0.104 ± 0.036 nmols/ UCS) and complex IV 
(0.231 x 10-3 K.sec-1.unit citrate synthase-1, normal range 1.124 ± 0.511) with normal 
activities of complex II and III. A significant decrease in quantitative mtDNA levels (<10% of 
aged-matched controls) was detected in muscle by RT-PCR, suggesting mtDNA depletion 
(Supplementary file 1, Supplementary figure 3), although screening of the TK2, RRM2B and 
POLG genes encoding proteins involved in mtDNA maintenance failed to detect any 
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candidate pathogenic variants. Her karyotype was normal and deletion of SMN1 was 
excluded.  
 
Decreased steady-state levels of multiple respiratory chain complexes in skeletal muscle, 
but not in fibroblasts   
Immunoblotting for mitochondrial proteins in skeletal muscle detected decreased steady-state 
levels of subunits of complexes I, IV and V, which was confirmed on blue-native 
polyacrylamide gel-electrophoresis (BN-PAGE) (Fig. 2a-d). The involvement of complexes 
I, IV and V but not complex II suggests a defect involving mtDNA expression or translation, 
since complex II is the only OXPHOS complex which does not contain subunits encoded by 
mtDNA. No significant decrease in the expression of the mitochondrial respiratory chain 
complexes was detected in fibroblasts. Reduced levels of SLC25A21 was found by 
immunoblotting in the patient`s fibroblasts suggesting that the mutation slightly affects 
expression or turnover of the protein (Fig. 2e-g).  
 
The p.(Lys232Arg) variant inactivates the transport function of SLC25A21 
Mitochondrial carriers, like SLC25A21, have a single substrate binding site and a cytoplasmic 
and matrix salt bridge network, which regulate access to the substrate binding site from either 
side of the membrane16. The pathogenic p.(Lys232Arg) variant affects the matrix salt bridge 
network of the SLC25A21, as Lys232 is predicted to form a salt bridge interaction with 
Glu130 of the neighbouring domain (Fig. 3a). Although the predicted amino acid substitution 
is conservative, it may prevent the interaction or cause other interactions that may ablate the 
function of the protein (Fig. 3b). To study the effect of the genetic variant on transport of 2-
oxoglutarate, truncated versions of the human wild-type and disease variant p.(Lys232Arg) 
were expressed in the cytoplasmic membrane of Lactococcus lactis under control of the Nisin 
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A promoter17. Expression levels of the wild-type and the p.(Lys232Arg) variant were similar, 
indicating the mutation does not affect expression and insertion of the carrier in lactococcal 
membranes (Fig. 3d). Wild-type SLC25A21 transported 2-oxoglutarate at a similar rate as the 
orthologous yeast ODC1 and ODC2 as measured by the uptake of [14C]-labelled 2-
oxoglutarate into fused membrane vesicles in exchange for incorporated unlabelled 
substrate18. In contrast, the p.(Lys232Arg) variant of SLC25A21 did not transport 2-
oxoglutarate above background levels, indicating that the function of the transport protein was 
completely impaired (Fig. 3c). This is consistent with the equivalent mutation in the bovine 
mitochondrial oxoglutarate carrier, p.(Lys244Arg), which also showed no discernible uptake 
above background18. The matrix salt bridge network is a highly conserved feature of 
mitochondrial carriers and is critical for their function. Thus, we conclude that the 
p.(Lys232Arg) variant causes SLC25A21 deficiency.  
 
Computational modelling of mitochondrial oxodicarboxylate carrier (SLC25A21) 
deficiency predicts build-up of degradation intermediates 
To investigate the consequences of impaired oxodicarboxylate transport by SLC25A21, we 
simulated its effects using the MitoCore computer model of central metabolism10. The model 
provides comprehensive coverage of central metabolism, including pathways for the 
degradation of lysine and tryptophan. SLC25A21 is modelled as four separate transport steps 
to reflect its characterized substrate specificity (2-oxoadipate for oxoglutarate, L-2-
aminoadipate for oxoglutarate) and forward and reverse directions6. We altered the model to 
allow the production and efflux of various lysine and tryptophan intermediates by including 
additional reactions and ‘sinks’. First, the model was simulated to maximise ATP production 
using a mixture of ‘fuel’ metabolites such as glucose, lactate, fatty acids and a forced 
minimum uptake of L-lysine and L-tryptophan approximated from physiological 
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measurements taken from rat heart tissue. The mitochondrial oxodicarboxylate carrier 
deficiency was then simulated by disabling the corresponding transport steps in the model. 
These simulations showed that although ATP production and respiratory chain fluxes were 
maintained, there was an increased accumulation of L-pipecolic acid and quinolinic acid, 
which are intermediates of tryptophan and lysine degradation (Fig. 4a). However, 
accumulation of other intermediates, such as L-kynuerine, xanthurenate, picolinate, L-2-
aminoadipate and 2-oxoadipate, was not observed. To identify alternative metabolites, the 
efflux of L-pipecolic acid and quinolinic acid were disabled in separate simulations. These 
simulations identified the efflux of 2-oxoadipate as a plausible alternative, as it had no impact 
on ATP production or central metabolism in general. 
 
Metabolic analysis detects increased levels of oxoadipate, quinolinic acid and pipecolic 
acid 
Mass spectrometry-based analysis of urine samples derived from the mitochondrial 
oxodicarboxylate carrier deficient patient compared to unrelated controls showed increased 2-
oxoadipate, quinolinic and pipecolic acid levels in urine samples, as predicted by the 
metabolic modelling (Fig. 4b). For comparison, we also studied three additional patients with 
distal spinal muscular atrophy who carried a mutation in dehydrogenase E1 and transketolase 
domain containing 1 (DHTKD1). DHTKD1 is upstream from SLC25A21 in the tryptophan 
and lysine amino acid degradation pathways (Fig. 4a)19, and, when dysfunctional, may cause 
similar metabolic changes. The observed elevation of oxoadipate, quinolinic and pipecolic 
acid levels in all of the patients supports the hypothesis that increases in these metabolites 
may contribute to spinal motor neuron abnormalities (Fig. 4b).  
 
Increased levels of oxoadipate and quinolinic acid selectively impair neurons 
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We supplemented control fibroblasts and neuronal cells (SH-SY5Y) with oxoadipate and 
quinolinic acid in concentrations, similar to the levels detected in the patients. There was no 
significant defect observed in fibroblasts, but a significant decrease of mitochondrial 
respiratory chain complexes was noted in neuronal cells on combined oxoadipate and 
quinolinic acid administration, suggesting a toxic effect of these metabolites for neurons (Fig. 
5a-d). In the treated neuronal cells mtDNA copy numbers showed a slight, but significant 
(<0.05) reduction (Supplementary file 1, Supplementary figure 4). Visualization of apoptotic 
cells stained with annexin V-FITC using confocal microscopy after 4 days of treatment with 
50 µM quinolinic acid and 5 µM 2-oxoadipate showed apoptosis in SHSY-5Y cells, while no 
apoptotic cells were detected in fibroblasts (Fig. 5e).  
 
DISCUSSION 
We report a patient with a novel mitochondrial disease affecting predominantly the spinal 
motor neurons and skeletal muscle due to dysfunction of the mitochondrial oxodicarboxylate 
carrier (SLC25A21). Interestingly, a 14q13.3 deletion involving the SLC25A21 gene has been 
reported with familial synpolydactyly20. However, this was suggested to occur due to the 
deletion of regulatory elements of the neighbouring developmental genes PAX9 and MIPOLI, 
which occur within introns of the SLC25A21 gene. Our patient did not have synpolydactyly, 
probably because the PAX9 and MIPOLI regulatory elements are unaffected. The patient 
presented with a wide range of metabolic and tissue specific mitochondrial abnormalities, 
including mitochondrial respiratory chain deficiencies involving complexes I and IV, 
associated mtDNA depletion and metabolic abnormalities. Pathogenic variants in another 
mitochondrial carrier SLC25A4 affecting most likely the substrate binding and mechanics of 
the carrier also present with severe mtDNA depletion which was explained by a deficiency of 
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ADP/ATP transport21. However, in contrast to mutations in SLC25A4, the oxodicarboxylate 
carrier is not directly involved in mitochondrial nucleotide transport.  
The disease is caused by the homozygous p.(Lys232Arg) mutation, which affects the 
highly conserved matrix salt bridge network motif PX[DE]XX[RK] and impairs 
oxodicarboxylate transport18. An equivalent mutation in the mitochondrial oxoglutarate 
carrier (p.Lys244Arg) also leads to a dysfunctional protein18. Mitochondrial carriers cycle 
between a matrix and cytoplasmic state, and the matrix network closes the carrier to the 
mitochondrial matrix, when the carrier is in the cytoplasmic state22. Although the arginine 
substitution will conserve the positive charge, it could impair network formation by changing 
the salt bridge geometry or by introducing additional polar interactions. We propose that the 
mutation causes mitochondrial oxodicarboxylate carrier deficiency since transport is 
completely abolished, leading to several metabolic abnormalities, which are causative for the 
severe, tissue specific defect of mitochondrial respiratory chain enzymes and result in tissue 
specific mtDNA depletion. However, we cannot exclude the possibility that the variant was 
not the sole cause of the phenotype23. 
To investigate the consequences of mitochondrial oxodicarboxylate carrier deficiency 
on metabolism, we simulated its effects using the MitoCore computer model of central 
metabolism10. The simulations predicted that three metabolites would accumulate: 2-
oxoadipate, L-pipecolic and quinolinic acid. Targeted metabolic analysis by mass 
spectroscopy confirmed the modelling results by showing an increase in the levels of these 
metabolites in the patient’s urine. To corroborate a pathogenic role for these amino acid 
degradation intermediates in spinal motor neurons, we performed metabolic testing in three 
previously reported19 patients who carried a pathogenic variant in the gene for dehydrogenase 
E1 and transketolase domain containing 1 (DHTKD1) gene an enzyme that is part of both 
lysine and tryptophan degradation pathways, and catalyses the decarboxylation of 2-
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oxoadipate to glutaryl-CoA. Mutations in DHTKD1 can be asymptomatic or cause 2-
aminoadipic 2-oxoadipic aciduria (AMOXAD), resulting in symptoms including a mild to 
severe neurological phenotypes, such as muscular hypotonia, or autosomal dominant 
peripheral neuropathy24,25 and decreased mtDNA copy number, which could be due to 
reduced mitochondrial biogenesis26. However, DHTKD1 dysfunction as a cause of inherited 
peripheral neuropathy is still debated due to these heterogeneous clinical presentations. Our 
results show, that the levels of all three metabolites were elevated, which is consistent with 
literature reports of patients with DHTKD1 deficiency24. The lower levels of 2-oxoadipate 
seen in the urine of these patients compared to SLC25A21 deficiency is presumably due to 
the transport of 2-oxoadipate into the mitochondrial matrix where it cannot be excreted. 
Pipecolic acid levels are increased in several related peroxisome disorders including 
Zellweger Syndrome27, infantile Refsum disease28 and neonatal adrenoleukodystrophy29, as 
well as the lysine degradation disorder hyperlysinemia type I30, caused α-aminoadipate 
semialdehyde synthase deficiency. Zellweger Syndrome presents with neurological 
dysfunction, craniofacial abnormalities, and liver dysfunction31, infantile Refsum disease 
presents with retinitis pigmentosa, peripheral neuropathy, cerebellar ataxia28, neonatal 
adrenoleukodystrophy presents with hypotonia and convulsions29, whereas hyperlysinemia 
presents with seizures and mildly delayed psychomotor development30. Despite these 
disorders sharing a common phenotype of neurological dysfunction, it has been suggested that 
in Zellweger Syndrome raised pipecolic acid levels are not the direct cause of pathology but 
arise as a benign consequence31 and cases of hyperlysinemia type I have been reported to be 
asymptomatic32.   
Quinolinic acid is a precursor for NAD+ biosynthesis33-35, and so may have 
contributed to some of the patient’s mitochondrial abnormalities due to a NAD+ deficiency. It 
is also a potent neurotoxin with high tendency to form free radicals, and is involved in several 
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neuroinflammatory disorders36,37. Quinolinic acid at elevated concentrations causes DNA 
damage, NAD+ depletion, increased nitric oxide formation, and cell death in neurons and 
astrocytes33. Quinolinic acid exerts its cytotoxicity37 by causing over-stimulation of the N-
methyl-D-aspartate (NMDA) receptor, which through free radicals leads to irreversible 
inhibition of complex I, complex II, ATP synthase, aconitase, creatine kinase, superoxide 
dismutase and mitochondrial DNA damage38. In addition, quinolinic acid forms a complex 
with Fe2+ 32-34 that may result in iron sequestration and probably resulted in the microcytic 
anaemia in the SLC25A21-deficient patient. Quinolinic acid also depletes glutathione in 
astrocytes via peroxynitrite, causing significant decreases in activity of complexes I and II39, 
which is consistent with the biochemical tests on our patient’s respiratory complexes. The 
presence of elevated lactate levels in the cerebrospinal fluid of the patient may be related to 
the mitochondrial enzyme defect, but may also be consistent with the increased lactate 
dehydrogenase (LDH) activity seen with quinolinic acid neurotoxicity33,34,36-39.  
Lastly, we tested the effect of quinolinic acid and 2-oxoadipate on neuronal cells and 
fibroblasts. There was a significant decrease of mitochondrial respiratory chain complexes in 
neuronal cells, but not fibroblasts, whereas apoptotic cells were only seen with a combination 
of the two metabolites in neuronal cells. We also detected a significant decrease in mtDNA 
copy number in the treated neurons (Supplementary file 1, Supplementary figure 4). In 
HepG2 cells with DHTKD1 silenced, a decrease in mtDNA copy number was reported and 
ascribed to reduced mitochondrial biogenesis26. Given that DHTKD1 and SLC25A21 are part 
of the same pathway, they may share common disease mechanisms, e.g. due to quinolate 
accumulation. Another example of a metabolic defect in the TCA cycle associated with low 
mtDNA copy numbers are mutations in SUCLA2 resulting in mitochondrial 
encephalomyopathy and mtDNA depletion. 
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Our data suggest that 2-oxoadipate and quinolinic acid are selectively toxic for spinal 
motor neurons and their increased levels through disrupted tryptophan and lysine degradation 
may contribute to neuropathy.  
In light of our findings, we have initiated a low lysine and tryptophan diet for the 
patient, which is used to treat glutaric aciduria type I40 although so far without significant 
clinical benefit in the patient. Follow-up examinations of the patient will enable a better 
estimation of the efficacy of dietary interventions.  
In summary, we combined a wide range of genetic, biochemical, molecular, metabolic 
and bioinformatics techniques to pinpoint the pathomechanism resulting from a novel 
mitochondrial carrier protein deficiency. Each of these techniques were needed to support the 
molecular diagnosis, highlighted important targets and helped to better understand the 
pathomechanism of disease in this patient, and also provided important insights for studies in 
other neurological and metabolic diseases.       
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LEGENDS FOR FIGURES 
Figure 1. Clinical and laboratory investigations in the patient 
(a) The patient has a severe distal and proximal weakness affecting the hands and feet and she 
is wheelchair bound. (b) Sanger sequencing detected the homozygous c.695A>G, 
p.(Lys232Arg) mutation in the patient, while both parents were heterozygous carriers of this 
mutation, and the healthy sister was wild type. (c) Muscle histology showed some groups of 
atrophic fibres and groups of hypertrophic fibres, typically seen in spinal muscular atrophy. 
ATPase pH 4.2 staining demonstrates a significant type grouping, in support of the 
neurogenic atrophy. (d) H&E, COX, SDH, COX-SDH; COX is generally weak across the 
section, also detected in the sequential assay.  
 
Figure 2. Immunoblotting and BN-PAGE in skeletal muscle and fibroblasts 
(a-b) In skeletal muscle immunoblotting detected decreased steady-state levels of 
mitochondrial OXPHOS complex subunits for complexes I, III, IV and V. (c-d) BN-PAGE 
detected reduced complexes I, IV and V. (e) Immunoblotting detected slightly reduced 
SLC25A21 in the patient`s fibroblasts, while (f) mitochondrial OXPHOS proteins were 
normal. (g) BN-PAGE detected normal respiratory chain complexes in the patient`s cell line. 
Nuclear-encoded GAPDH, VDAC, SDHA or SDHB proteins were used as loading controls. 
Abbreviations: Complex I (CI); complex II (CII); complex III (CIII); complex IV (CIV); 
complex V / F1FO ATP synthase (CV); (GAPDH); cytochrome c oxidase 1 (COX1); 
cytochrome c oxidase 2 (COX2); voltage-dependent anion-selective channel (VDAC); NADH 
dehydrogenase ubiquinone 1 beta subcomplex subunit 8 (NDUFB8); F1FO ATP synthase 
subunit (ATP5A); succinate dehydrogenase subunit A (SDHA); succinate dehydrogenase 
subunit B (SDHB); ubiquinol-cytochrome c reductase core protein II (UQCRC2). 
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Figure 3. The p.(Lys232Arg) mutation interferes with the formation of the matrix salt 
bridge network and impairs function of the mitochondrial oxodicarboxylate carrier 
(SLC25A21).  
(a) Membrane view of the comparative homology model of human SLC25A21 generated 
with SwissModel (Arnold et al., 2006) based on the structure of the bovine ADP/ATP carrier 
(alignment shown in Supplementary file 1. Supplementary figure 1). The matrix and 
cytoplasmic salt bridge network are shown in dark blue and cyan, respectively. The mutated 
lysine 232 is shown in yellow. The residues of the proposed substrate binding site are shown 
in green and the substrate 2-oxoglutarate is shown in an orange ball and stick representation. 
(b) Cytoplasmic view showing the residues involved in the formation of the matrix salt bridge 
network in dark blue. The most probable side chain conformations of the p.(Lys232Arg) 
mutation are shown in magenta, indicating that the substitution might impair binding to 
Glu131 and might lead to other polar interactions. (c) The 2-oxoglutarate uptake curves of 
SLC25A21 and SLC25A21_p.(Lys232Arg). Fused membrane vesicles of Lactococcus lactis 
expressing SLC25A21 (triangles) or SLC25A21_p.(Lys232Arg) (circles) were pre-loaded 
with 5 mM 2-oxoglutarate and transport was initiated with the external addition of 1.5 μM 
[14C]-2-oxoglutarate. Membranes of the uninduced SLC25A21 strain (squares) show 
background binding, indicating that SLC25A21_p.(Lys232Arg) does not transport above 
background. (d) Expression levels of the wild-type and mutant SLC25A21 were similar, 
indicating the mutation did not affect expression and insertion of the carrier in lactococcal 
membranes. (e) The 2-oxoglutarate transport rates of SLC25A21 and 
SLC25A21_p.(Lys232Arg) after correction for background binding. The error bars represent 
the standard deviation of four technical repeats. Student t-tests, significant uptake above 
background: P > 0.05, not significant (NS); P > 0.01, *; P > 0.001, **; P > 0.0001, ***; P < 
0.0001, ****. 
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Figure 4. Metabolism of tryptophan and lysine is impaired by mitochondrial 
oxodicarboxylate carrier deficiency. 
(a) The degradation pathways of tryptophan and lysine runs through the mitochondrion, 
which links it to the generation of ATP through the production of NADH, which leads to the 
reduction of the co-enzyme Q (Q) via complex I, the production of acetyl-CoA, which enters 
the TCA cycle, and through the reduction of the Q pool directly via glutaryl-CoA 
dehydrogenase and the electron-transferring flavoprotein (dashed line). The metabolic model 
predicts an increase in quinolinic acid and picolinate levels, which are spontaneously (*) 
formed from semi-aldehydes, and in oxoadipate and pipecolate levels, as the import of 2-
oxoadipate and 2-aminoadipate into mitochondria is blocked by mitochondrial 
oxodicarboxylate carrier deficiency (red arrows). These intermediates may have neurotoxic 
effects, leading to neuropathy. (b) Targeted metabolic analysis detected increased 2-
oxoadipate, quinolinic acid and pipecolic acid in the patient and in three other patients 
carrying DHTKD1 mutations.  
 
Figure 5. Administration of 2-oxoadipate and quinolinic acid in vitro was more toxic for 
neuronal cells than fibroblasts 
(a) Western blot analysis detected normal expression in control fibroblasts after 
supplementation of 50 μM quinolinic acid and 5 μM 2-oxoadipate after 4 days. (b) 
Quantification of protein levels were normalised to porin. (c) In human neuroblastoma cells 
(SHSY-5Y) the supplementation of the 50 μM quinolinic acid and 5 μM 2-oxoadipate 
resulted in significantly reduced levels affecting all five OXPHOS complexes, as shown in 
(d) (n=3 experimental replicates). P values are from One-Way ANOVA test. Where indicated 
* P<0.05. (e) Visualization of apoptotic cells stained with annexin V-FITC using confocal 
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microscopy after treatment with only 50 μM quinolinic acid and combination of 50 μM 
quinolinic acid and 5 μM 2-oxoadipate.  Cells were supplemented for 4 days before staining. 
DAPI staining was used as nuclear marker.  Top row shows fibroblasts where no Annexin V 
positive cells were detected in any treatment. Bottom row shows SHSY-5Y cells: Indication 
annexin V positive cells were identified after double supplementation. Scale bar = 50μM. 
 
Supplementary file 1 contains Supplementary methods and 4 Supplementary figures. 
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Supplementary methods 
SDS-PAGE and BN-PAGE analysis 
100 µg of n-dodecyl-β-d-maltoside solubilised mitochondria were separated on 4-16% native 
polyacrylamide BisTris gel (Life Technologies) followed by an electrophoretic transfer and 
immunoblotting. OXPHOS subunits and complexes were detected using antibodies against 
NDUFB8 (ab110242, Abcam), SDHA (ab14715, Abcam), UQCRC2 (ab14745, Abcam), 
COX1 (ab14705, Abcam), ATP5A (ab14748, Abcam), OXPHOS cocktail (MS601 
MitoSciences) and anti-mouse-HRP conjugated secondary antibodies (P0260, DAKO). 
VDAC (ab14734, Abcam) and GAPDH (Santa-Cruz sc-25778 HRP) were used as loading 
controls. An anti-SLC25A21 antibody produced in rabbit (ab167033, Abcam) was used at 
1:1,000 dilution for one hour, followed by an anti-rabbit-HRP conjugate produced in goat 
(Millipore, AP132P) at 1:10,000 dilution for a further hour. The membranes were developed 
using Amersham ECL Western blotting detection system. 
 
Transport studies of SLC25A21 expressed in L. lactis 
The plasmid was transformed in L. lactis strain NZ9000 by electroporation. Vectors were 
isolated by miniprep (Qiagen), according to the manufacturer’s instructions with one 
alteration; 10 mg/ml lysozyme was added to the lysis buffer and the resuspended cells were 
incubated at 55 °C for twenty minutes prior to lysis; successful transformants were confirmed 
by sequencing. 
Pre-cultures of L. lactis were obtained by inoculating M17 medium supplemented 
with 1% (w/v) glucose and 5 μg/ml chloramphenicol from glycerol stocks and incubating the 
cultures overnight at 30 °C with no aeration. Cells were diluted to a starting A600 of 0.1 in 
fresh M17 medium supplemented with 1% (w/v) glucose and 5 μg/ml chloramphenicol and 
Supplementary file
incubated at 30 °C with no aeration until the A600 reached 0.5. Expression of the 
recombinant protein was induced by addition of nisin A with a dilution of 1:10,000 of spent 
M17 medium from nisin A-excreting L. lactis strain NZ9700. Cells were grown for a further 
3 h at 30 °C, harvested by centrifugation (6000 x g, 10 min, 4 °C), resuspended in PIPES 
buffer (10 mM PIPES pH 7.0, 50 mM NaCl) and collected by centrifugation as before. Cells 
were subsequently resuspended in 50 ml PIPES buffer and disrupted mechanically with a cell 
disruptor (Constant Cell Disruption Systems) at 33 kpsi. Cell debris was removed by 
centrifugation (10,800 x g, 15 min, 4 °C), and the membranes collected by ultracentrifugation 
(138,000g, 1 h, 4 °C). Pellets were resuspended in PIPES buffer and stored in liquid nitrogen. 
E. coli polar lipid extract and egg yolk phosphatidylcholine (20 mg/ml in chloroform) 
were mixed in a 3:1 mass ratio. The chloroform was evaporated under a stream of nitrogen, 
the lipids were resuspended in PIPES buffer with a homogenizer to a final concentration of 
20 mg/ml and frozen in liquid nitrogen. 
To make membrane fusions, 1 mg L. lactis membranes was mixed with 5 mg 
liposomes, diluted to a final volume of 900 µL with PIPES, and fused by seven cycles of 
freezing in liquid nitrogen and thawing at room temperature before storage in liquid nitrogen. 
The membrane vesicle fusions were thawed and 100 µl 50 mM 2-oxoglutarate added. 
Vesicles were extruded 11 times through a 1-μm polycarbonate filter, passed through a pre-
equilibrated PD10 column to remove external substrate, collected in 1.6 ml PIPES buffer, and 
diluted four-fold before use. 
 
Metabolite analysis by mass spectrometry 
Quantitation of oxoadipate, quinolinic acid, glycolate, lactate, pyruvate, citrate, isocitrate, 
succinate, fumarate, malate, α-hydroxyglutarate and 2-oxoglutarate was carried out by pre-
analytical chemical derivatization - UPLC-MRM/MS using 3-nitrophenylhydrazine (3-NPH) 
as the derivatizing reagent as described. Quantitation of pipecolate and amino acids was 
performed by pre-analytical chemical derivatization – UPLC-MRM/MS using dansyl 
chloride as the derivatizing reagent. A stock solution that contained the standard substances 
of pipecolate and 21 amino acids, at an equal concentration of 1 mM, was prepared in 70% 
acetonitrile. This solution was diluted with the same solvent, and step by step at a same 
dilution ratio of 1:4 (v/v), to have a concentration range of 3.8 nM to 62.5 μM.  For 
derivatization, 30 μl of each supernatant from the samples or each standard solution was 
mixed with 30 μl of a mixed solution that contained predefined amounts of 13C or D-isotope-
labeled analogues as internal standards for the 22 individual analytes, 60 μl of 50 mM dansyl 
chloride solution in acetonitrile, and 30 μl of borate buffer (pH 9.2). The mixtures were 
reacted at 40 °C for 45 min, and after reaction, each solution was diluted with 150 μl of 
water.  Twenty microlitre aliquots were injected for UPLC-MRM/MS runs with positive-ion 
detection. The chromatographic separation was carried out on an Agilent Eclipse RRHD C18 
column (2.1 mm I.D. x 150 mm, 1.8 μm) with 0.1% formic acid in water (A) and acetonitrile-
isopropanol-formic acid (50:50:0.1, v/v/v) as the mobile phase for binary-solvent gradient 
elution. The elution gradient was 20% to 50% B in 5 min; 50% to 100% B in 10 min, 
followed by 4 min column equilibrium between injections.  The flow rate was 0.3 ml/min and 
the column temperature was 50 °C. The concentrations of the metabolites in each sample 
were calculated from linearly-regressed calibration curves for individual compounds with 
internal calibration. 
 
Study of apoptosis in cell cultures with Annexin V-FITC/Propidium Iodide staining 
Cell apoptosis was assessed using an Annexin V-FITC/Propidium Iodide (PI) Apoptosis 
Detection Kit (Abcam). Briefly, the cells treated by 2-oxoadipic acid and quinolinic acid 
were washed and labelled with annexin V-FITC conjugate and PI solution at room 
temperature for 15 min in the dark. Immunofluorescence images were collected using a Zeiss 
Axioimager Z1 fluorescence microscope equipped with Zeiss Apotome 2 (Zeiss, Germany). 
Acquired images were processed with ZEN (2012) software. 
  
Supplementary figure 1: alignment of SLC25A21 against BtAAC1 using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) 
 
Supplementary figure 2: alignment of SLC25A21 against the N-terminal truncation Δ2-4 using 
Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) 
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Supplementary figure 3: Muscle mtDNA copy number was determined in the patient and compared 
to controls (n=25) as previously described1, expressing the data as a % of mean control mtDNA copy 
number. Patient muscle revealed a significant mtDNA depletion (<10% of age-matched controls). 
 
 
 
 
 
 
 
Supplementary figure 4: MtDNA copy number measurement after 5 days supplementation of 2-
oxoadipate and quinolinic acid in vitro in SHSY-5Y cells showed slight, but significant reduction of 
mtDNA on paired t-test. The two-tailed P value equals 0.0369. 
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Reference: 
1. Blakely, E. et al. Novel mutations in the TK2 gene associated with fatal mitochondrial 
DNA depletion myopathy. Neuromusc. Disord. 18, 557-560. doi: 10.1016/j.nmd.2008.04.014 
(2008). 
 
